Olympus scopes linked to US superbug outbreaks

FDA discovers a failure to alert regulators about 2012 infections, and no standard reporting procedure.

August 18, 2015

WASHINGTON — Federal regulators have uncovered new violations by the manufacturer of medical scopes recently linked to outbreaks of deadly “superbug” bacteria at US hospitals.

Olympus Corp. failed to alert regulators to a cluster of 16 infections in patients who underwent procedures with the company’s scope in 2012, according to a warning letter posted online by the Food and Drug Administration. Olympus did not report the problems to the FDA until 2015, when the company was already under scrutiny for a more recent series of outbreaks.

Medical device manufacturers are required to report serious device problems to the FDA within 30 days of learning about them. The infections reported to the company involved a bacterial strain called pseudomonas, which can cause pneumonia, severe sickness and death in hospital patients.

Additionally, FDA inspectors found that the company has no standard procedure for promptly reporting serious problems with its devices, a requirement for medical device companies. The FDA inspected four company sites in Japan and the US between March and April this year.

A spokesman for the Tokyo manufacturer said in a statement: “We are reviewing the FDA’s warning letter so that we can provide the required response in a timely manner.”

Medical scopes from Olympus were linked to infections of antibiotic-resistant bacteria at two separate Los Angeles hospitals earlier this year. Hospital staff at Cedars-Sinai and UCLA medical centres said the infections occurred despite following Olympus’ instructions for cleaning the devices, known as duodendoscopes.

Olympus is the market leader for duodenoscopes in the U.S., accounting for about 85 per cent of sales, according to the FDA.

The specialized scopes consist of a flexible fiber-optic tube that is inserted down the throat into the stomach and small intestine to diagnose and treat conditions in the pancreas and bile ducts. The tip of the scope includes movable instruments designed to remove tumors, gallstones and other blockages. But this complex design also makes the instruments extremely difficult to clean. Bodily fluids and other debris can stay in the device’s joints and crevices even after cleaning and disinfection.

Since 2013, there have been eight outbreaks of antibiotic-resistant bacteria linked to the devices at US hospitals, according to government figures.

The FDA also posted warning letters to two other scope manufacturers – Hoya Corp. and Fujifilm Corp. – citing problems with the testing, design, reporting and quality control of their devices. All of the letters are dated Aug. 12. The companies are given 15 business days to respond with their plans to fix the problems.

Fujifilm said in a statement that it “takes the issue very seriously and is working closely with FDA.” Hoya Corp. did not immediately respond to a request for comment.

The FDA previously disclosed that Olympus did not seek federal clearance for the latest version of its duodenoscope, which it began selling in 2010.

Despite these problems, the FDA previously ruled it would keep the devices on the market because they fill an important need in a half-million procedures performed each year.

Have your say:

Your email address will not be published. Required fields are marked *